MedTrace Logo

LISA-study : Levothyroxin in Nodular Goiter

NCT00277589 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1024

Last updated 2009-12-04

No results posted yet for this study

Summary

Primary objective:

* To evaluate change in total volume of all nodules.

Secondary objectives:

* To evaluate change in goiter volume after a 12-months treatment, number of nodules and echogenicity of nodules.

Conditions

  • Goiter, Nodular

Interventions

DRUG

Levothyroxin-Na

1 tablet 30 minutes before breakfast

DRUG

Levothyroxine-Na + iodide

1 tablet 30 minutes before breakfast

DRUG

Iodide

1 tablet 30 minutes before breakfast

DRUG

Placebo

1 tablet 30 minutes before breakfast

Sponsors & Collaborators

Principal Investigators

  • Katrin Roscher · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00277589 on ClinicalTrials.gov